TAIHO VENTURES, LLC
A $400M corporate venture arm of Taiho Pharmaceutical, investing in early-stage companies in oncology, immunology, and urology — mostly research to pre-IND.
WHERE WE INVEST
Three therapeutic areas Taiho has been doing the work in for sixty years — plus the adjacent platforms that change what’s possible inside them.
Solid tumors, hematologic malignancies, and the targeted-therapy and ADC programs that come after them. The therapeutic area Taiho was founded on in 1963.
Autoimmune and inflammatory disease, with a working interest in the overlap with oncology — IO combinations, T-cell engagers, and the next wave of cell therapies.
Genitourinary cancers and the broader urology pipeline. Less crowded than the headline indications, and an area where Taiho has been operating commercially for decades.
Gene and cell therapy, RNA, AI-led drug discovery, and the tooling underneath them. We back platforms when the science applies to a program we’d back on its own.
WHY PARTNER WITH US
You don’t get a check and a Slack channel. You get a partner who knows the regulatory path because they walked it — the people across the table from you have taken compounds through phase II, phase III, and to approval.
Taiho is a privately-held subsidiary of Otsuka with no quarterly-earnings clock. The fund’s timeline is the science’s timeline. We can hold through a difficult clinical readout and follow on through the round you didn’t plan to need.
Taiho has approved drugs on the market across three continents. When the data lands, you have a built-in conversation about co-development, licensing, or commercial partnership — with people who can actually pull the lever.
No drive-by board members, no rotating cast. Whoever shows up to your first board meeting is the person who keeps showing up — through the next round, the next readout, and the next strategic decision.
EXPLORE OUR WORK
Stage, check size, therapeutic area, board involvement — written so a founder can read them in five minutes and tell whether to send the deck.
Read onTwenty-five companies and counting, mostly entered at research to pre-IND. A few we picked up at IND or proof-of-concept when the science was right.
Read onThe people on the partnership team and the operating partners they pull in — chemists, regulatory leads, commercial heads, biostatisticians.
Read onA short form, an honest read, a written response. We close the loop on every submission, including the ones that aren’t a fit.
Read onINVESTMENT CRITERIA
The short version of how we make decisions, by therapeutic area. The long version is on the criteria page, with the diligence questions we actually ask.
| Therapeutic area | Entry stage | Initial check | Geography | Board involvement | Detail link |
|---|---|---|---|---|---|
| Oncology | Research to pre-IND | $3M–$15M | US, EU, Japan | Voting seat or observer | Detail |
| Immunology | Pre-IND to phase I | $5M–$20M | US, EU, Japan | Voting seat | Detail |
| Urology | Pre-IND to proof-of-concept | $3M–$12M | US, EU | Voting seat or observer | Detail |
| Adjacent platforms | Seed to series B | $2M–$10M | Global | Observer | Detail |
A FEW FROM THE PORTFOLIO
Phosphatase-targeted small molecules
Research → IND
Immuno-oncology combinations
Phase II
Regulated induced proximity (RIPTAC)
Pre-IND
They asked the diligence questions our chemistry team had been arguing about for a year, and then they got on a plane to come argue them with us in person. The check came after we agreed on the experiment.
MORE RESOURCES
The full investment criteria
Stage, check size, geography, board involvement, the diligence questions we ask.
Submit a proposal
A short form, a written response within ten business days. Including for the ones that aren’t a fit.
Press & corporate inquiries
Quarterly portfolio updates, the Taiho parent-company filings, and a press contact for cycle-time inquiries.
